Janssen gains immunotherapies, boosts prostate portfolio with Aduro deal

Johnson & Johnson's Janssen Biotech will pay up to $359m in upfront and milestone fees plus royalties to expand the companies' Zytiga-led prostate cancer portfolio with programs based on Aduro BioTech's immunotherapy technology.